Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD).
All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law. SAMHSA (Substance Abuse and Mental Health Services Administration) and DEA are actively working on implementation of a separate provision of the Omnibus bill related to training requirements for DEA registration that becomes effective in June 2023. Prescribers can check back here for updates.
The DEA urges all registrants to be aware that:
Source of information above:
https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement
https://www.deadiversion.usdoj.gov/pubs/docs/A-23-0020-Dear-Registrant-Letter-Signed.pdf